Ascendis Pharma details warrant exercises, capital boost
Ascendis Pharma A/S reports the closing of a warrant exercise window for its outstanding warrants linked to ordinary shares.
Rhea-AI Filing Summary
Ascendis Pharma A/S reports the closing of a warrant exercise window for its outstanding warrants linked to ordinary shares. During this window, holders exercised warrants resulting in registered share capital increases of nominal DKK 177,267.
This raised the company’s total share capital to nominal DKK 66,189,926 through the issuance of 177,267 new ordinary shares. Ascendis received average cash consideration of approximately USD $121.57 per share, based on the DKK-USD exchange rate on June 29, 2026. The company’s articles of association were updated to reflect the new capital and are included as an exhibit.
Positive
- None.
Negative
- None.
Key Figures
New shares issued: 177,267 shares
Capital increase (nominal): DKK 177,267
Total nominal share capital: DKK 66,189,926
+1 more
4 metrics
New shares issued
177,267 shares
Ordinary shares issued from warrant exercises during window
Capital increase (nominal)
DKK 177,267
Aggregate nominal share capital increase from exercised warrants
Total nominal share capital
DKK 66,189,926
Share capital after warrant-driven capital increase
Average cash per share
USD $121.57 per share
Average cash consideration based on DKK-USD rate on June 29, 2026
Key Terms
warrants, exercise window, articles of association, Form 6-K, +2 more
6 terms
warrants financial
"an exercise window closed for the Company’s outstanding warrants exercisable for the Company’s ordinary shares"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
exercise window financial
"On June 29, 2026, an exercise window closed for the Company’s outstanding warrants"
articles of association regulatory
"The Company’s articles of association were amended accordingly and are attached hereto as Exhibit 1.1."
A company's articles of association are its written rulebook that sets how the business is run, how decisions are made, and what rights owners and directors have—covering voting, meetings, appointment and removal of directors, share classes and dividend policies. For investors, these rules matter because they determine how easily control can change, what protections minority owners have, and how corporate actions (like issuing new shares or changing leadership) are approved, much like a home’s bylaws shaping what residents can and cannot do.
Form 6-K regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
registration statements on Form S-8 regulatory
"incorporated by reference into the registration statements on Form S-8"
Form F-3 regulatory
"and Form F-3 (Registration Numbers 333-209336 and 333-282196) of Ascendis Pharma A/S"
Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Ascendis Pharma (ASND) announce in this Form 6-K?
Ascendis Pharma reported the closing of a warrant exercise window that resulted in new shares being issued and a higher nominal share capital. The filing also updates its articles of association to reflect these changes and incorporates the report into existing registration statements.
Were Ascendis Pharma’s articles of association changed in this filing?
Yes. The company amended its articles of association to reflect the higher nominal share capital following the warrant exercises. The updated articles of association are attached as Exhibit 1.1, providing formal documentation of the revised capital structure and related corporate details.
AI-generated analysis. How Rhea-AI works. Not financial advice.
